David J Reiss
Overview
Explore the profile of David J Reiss including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
2051
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sivakumar S, Jainarayanan A, Arbe-Barnes E, Sharma P, Ni Leathlobhair M, Amin S, et al.
Nat Commun
. 2025 Feb;
16(1):1397.
PMID: 39915477
Pancreatic ductal adenocarcinoma has a dismal prognosis. A comprehensive analysis of single-cell multi-omic data from matched tumour-infiltrated CD45+ cells and peripheral blood in 12 patients, and two published datasets, reveals...
2.
Reiss D, Nakayama Y, Weng A, Stokes M, Sehn L, Steidl C, et al.
Leukemia
. 2024 Apr;
38(5):1164-1168.
PMID: 38575670
No abstract available.
3.
Peterson E, Brooks A, Reiss D, Kaur A, Do J, Pan M, et al.
Cell Rep
. 2023 Aug;
42(8):112875.
PMID: 37542718
The success of Mycobacterium tuberculosis (Mtb) is largely attributed to its ability to physiologically adapt and withstand diverse localized stresses within host microenvironments. Here, we present a data-driven model (EGRIN...
4.
Olson N, Ragan S, Reiss D, Thorpe J, Kim Y, Abramson J, et al.
Mol Cancer Ther
. 2023 Jan;
22(3):406-418.
PMID: 36595660
In the TRANSCEND NHL 001 study, 53% of patients with relapsed/refractory large B-cell lymphoma (LBCL) treated with lisocabtagene maraleucel (liso-cel) achieved a complete response (CR). To determine characteristics of patients...
5.
Wall M, Turkarslan S, Wu W, Danziger S, Reiss D, Mason M, et al.
NPJ Precis Oncol
. 2021 Jun;
5(1):60.
PMID: 34183722
Despite recent advancements in the treatment of multiple myeloma (MM), nearly all patients ultimately relapse and many become refractory to multiple lines of therapies. Therefore, we not only need the...
6.
Danziger S, McConnell M, Gockley J, Young M, Rosenthal A, Schmitz F, et al.
PLoS Med
. 2020 Nov;
17(11):e1003323.
PMID: 33147277
Background: The tumor microenvironment (TME) is increasingly appreciated as an important determinant of cancer outcome, including in multiple myeloma (MM). However, most myeloma microenvironment studies have been based on bone...
7.
Aguilar B, Gibbs D, Reiss D, McConnell M, Danziger S, Dervan A, et al.
Gigascience
. 2020 Jul;
9(7).
PMID: 32696951
Background: Mechanistic models, when combined with pertinent data, can improve our knowledge regarding important molecular and cellular mechanisms found in cancer. These models make the prediction of tissue-level response to...
8.
Wainberg Z, Hochster H, Kim E, George B, Kaylan A, Chiorean E, et al.
Clin Cancer Res
. 2020 Jun;
26(18):4814-4822.
PMID: 32554514
Purpose: Assess safety and efficacy of nivolumab plus -paclitaxel and gemcitabine in patients with locally advanced/metastatic pancreatic cancer in a two-part, open-label, phase I trial. Patients And Methods: Fifty chemotherapy-naive...
9.
Danziger S, Gibbs D, Shmulevich I, McConnell M, Trotter M, Schmitz F, et al.
PLoS One
. 2019 Nov;
14(11):e0224693.
PMID: 31743345
Immune cell infiltration of tumors and the tumor microenvironment can be an important component for determining patient outcomes. For example, immune and stromal cell presence inferred by deconvolving patient gene...
10.
Turkarslan S, Raman A, Thompson A, Arens C, Gillespie M, von Netzer F, et al.
Mol Syst Biol
. 2017 Mar;
13(3):919.
PMID: 28320772
Managing trade-offs through gene regulation is believed to confer resilience to a microbial community in a fluctuating resource environment. To investigate this hypothesis, we imposed a fluctuating environment that required...